Exploring the molecular biomarker utility of circCCT3 in multiple myeloma: A favorable prognostic indicator, particularly for R‐ISS II patients

Exploring the molecular biomarker utility of circCCT3 in multiple myeloma: A favorable prognostic indicator, particularly for R‐ISS II patients

Abstract Circular RNAs (circRNAs) are associated with the pathobiology of multiple myeloma (MM). Recent findings regarding circCCT3 support its involvement in the development and progression of MM, through microRNA sponging. Thus, we aimed to examine the expression of circCCT3 in smoldering and symp...

Full description

Bibliographic Details
Main Authors:	Maria Papatsirou, Christos K. Kontos, Ioannis Ntanasis‐Stathopoulos, Panagiotis Malandrakis, Diamantis C. Sideris, Despina Fotiou, Christine‐Ivy Liacos, Maria Gavriatopoulou, Efstathios Kastritis, Meletios A. Dimopoulos, Andreas Scorilas, Evangelos Terpos
Format:	Article
Language:	English
Published:	Wiley 2024-01-01
Series:	HemaSphere
Online Access:	https://doi.org/10.1002/hem3.34

Similar Items

P826: THE CIRCULAR RNA OF THE CHAPERONIN-CONTAINING TCP1 SUBUNIT 3 GENE (CIRC-CCT3) IS OVEREXPRESSED IN MULTIPLE MYELOMA AND PREDICTS A FAVORABLE PROGNOSTIC OUTCOME, INDEPENDENTLY OF THE R-ISS STAGING
by: Maria Papatsirou, et al.
Published: (2023-08-01)

A Molecular Signature of Circulating MicroRNA Can Predict Osteolytic Bone Disease in Multiple Myeloma
by: Aristea-Maria Papanota, et al.
Published: (2021-07-01)

High Prevalence of Anti-PF4 Antibodies Following ChAdOx1 nCov-19 (AZD1222) Vaccination Even in the Absence of Thrombotic Events
by: Evangelos Terpos, et al.
Published: (2021-07-01)

PB2127: REAL-WORLD EFFECTIVENESS AND SAFETY OF BELANTAMAB MAFODOTIN IN TRIPLE CLASS REFRACTORY PATIENTS WITH MULTIPLE MYELOMA
by: Ioannis Ntanasis-Stathopoulos, et al.
Published: (2023-08-01)

Prevalence of MGCS Among Patients With Monoclonal Gammopathies
by: Foteini Theodorakakou, et al.
Published: (2023-06-01)

Real-World Effectiveness and Safety of Belantamab Mafodotin Monotherapy in Triple-Class Refractory Multiple Myeloma
by: Ioannis Ntanasis-Stathopoulos, et al.
Published: (2023-07-01)

Use of Oral Antivirals Ritonavir-Nirmatrelvir and Molnupiravir in Patients with Multiple Myeloma Is Associated with Low Rates of Severe COVID-19: A Single-Center, Prospective Study
by: Vassiliki Spiliopoulou, et al.
Published: (2023-03-01)

Upfront Daratumumab With Lenalidomide and Dexamethasone for POEMS Syndrome
by: Maria Gavriatopoulou, et al.
Published: (2020-06-01)

Current and novel BTK inhibitors in Waldenström’s macroglobulinemia
by: Ioannis Ntanasis-Stathopoulos, et al.
Published: (2021-02-01)

miRNA-seq identification and clinical validation of CD138+ and circulating miR-25 in treatment response of multiple myeloma
by: Maria-Alexandra Papadimitriou, et al.
Published: (2023-04-01)

A Cancer-Related microRNA Signature Shows Biomarker Utility in Multiple Myeloma
by: Aristea-Maria Papanota, et al.
Published: (2021-12-01)

Pomalidomide- and dexamethasone-based regimens in the treatment of refractory/relapsed multiple myeloma
by: Despina Fotiou, et al.
Published: (2022-05-01)

P928: OCULAR ADVERSE EVENTS AND FUNCTIONAL IMPACT IN TRANSPLANT INELIGIBLE, NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS TREATED WITH BELANTAMAB MAFODOTIN, LENALIDOMIDE AND DEXAMETHASONE IN A PHASE 1/2 TRIAL
by: Evangelos Terpos, et al.
Published: (2023-08-01)

P861: PERSISTENT BONE MARROW AND IMAGING MRD NEGATIVITY AS CRITERIA TO STOP LENALIDOMIDE MAINTENANCE FOLLOWING ASCT: PRELIMINARY RESULTS OF A SINGLE-CENTER PROSPECTIVE COHORT STUDY
by: Panagiotis Malandrakis, et al.
Published: (2023-08-01)

P884: BELANTAMAB MAFODOTIN PLUS LENALIDOMIDE AND DEXAMETHASONE IN TRANSPLANT INELIGIBLE PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA: UPDATED RESULTS FROM THE PHASE 1/2 BELARD STUDY
by: Evangelos Terpos, et al.
Published: (2023-08-01)

B03: SKELETAL-RELATED EVENTS AND ABNORMAL MRI PATTERN AT DIAGNOSIS ARE ASSOCIATED WITH INFERIOR OVERALL SURVIVAL IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA
by: Evangelos Terpos, et al.
Published: (2022-04-01)

Tixagevimab/Cilgavimab as Pre-Exposure Prophylaxis against COVID-19 for Multiple Myeloma Patients: A Prospective Study in the Omicron Era
by: Ioannis Ntanasis-Stathopoulos, et al.
Published: (2023-09-01)

Daratumumab May Attenuate Cardiac Dysfunction Related to Carfilzomib in Patients with Relapsed/Refractory Multiple Myeloma: A Prospective Study
by: Evangelos Terpos, et al.
Published: (2021-10-01)

Robust Neutralizing Antibody Responses 6 Months Post Vaccination with BNT162b2: A Prospective Study in 308 Healthy Individuals
by: Evangelos Terpos, et al.
Published: (2021-10-01)

Circulating Soluble Urokinase-Type Plasminogen Activator Receptor Levels Reflect Renal Function in Newly Diagnosed Patients with Multiple Myeloma Treated with Bortezomib-Based Induction
by: Evangelos Terpos, et al.
Published: (2020-10-01)

Systemic AL Amyloidosis: Current Approaches to Diagnosis and Management
by: Despina Fotiou, et al.
Published: (2020-08-01)

Approach to Contemporary Risk Assessment, Prevention and Management of Thrombotic Complications in Multiple Myeloma
by: Despina Fotiou, et al.
Published: (2022-12-01)

SARS-CoV-2 Vaccines in Patients With Multiple Myeloma
by: Maria Gavriatopoulou, et al.
Published: (2021-03-01)

Management and Outcomes of Anti-CD38 Refractory Patients: The Impact of Retreatment and of Subsequent Therapies
by: Efstathios Kastritis, et al.
Published: (2023-11-01)

Newly Diagnosed Multiple Myeloma Patients with Skeletal-Related Events and Abnormal MRI Pattern Have Poor Survival Outcomes: A Prospective Study on 370 Patients
by: Nikolaos Kanellias, et al.
Published: (2022-05-01)

tRNA Derivatives in Multiple Myeloma: Investigation of the Potential Value of a tRNA-Derived Molecular Signature
by: Paraskevi Karousi, et al.
Published: (2021-12-01)

Comparison of Neutralizing Antibody Responses at 6 Months Post Vaccination with BNT162b2 and AZD1222
by: Evangelos Terpos, et al.
Published: (2022-02-01)

S178: SAFETY AND EFFICACY OF BELANTAMAB MAFODOTIN IN COMBINATION WITH RD IN NEWLY DIAGNOSED, TRANSPLANT INELIGIBLE MULTIPLE MYELOMA PATIENTS: A PHASE 1/2 STUDY BY THE HELLENIC SOCIETY OF HEMATOLOGY
by: E. Terpos, et al.
Published: (2022-06-01)

The neutralizing antibody response post COVID-19 vaccination in patients with myeloma is highly dependent on the type of anti-myeloma treatment
by: Evangelos Terpos, et al.
Published: (2021-08-01)

Aberrant Plasma Cell Contamination of Peripheral Blood Stem Cell Autografts, Assessed by Next-Generation Flow Cytometry, Is a Negative Predictor for Deep Response Post Autologous Transplantation in Multiple Myeloma; A Prospective Study in 199 Patients
by: Ioannis V. Kostopoulos, et al.
Published: (2021-08-01)

Efficacy and immune modulation associated with the addition of IMiDs to Daratumumab backbone in multiple myeloma patients refractory to both drug classes: resetting synergistic activity
by: Ioannis V. Kostopoulos, et al.
Published: (2024-02-01)

Second Booster BNT162b2 Restores SARS-CoV-2 Humoral Response in Patients With Multiple Myeloma, Excluding Those Under Anti-BCMA Therapy
by: Ioannis Ntanasis-Stathopoulos, et al.
Published: (2022-08-01)

Predictive Factors for Neutralizing Antibody Levels Nine Months after Full Vaccination with BNT162b2: Results of a Machine Learning Analysis
by: Dimitris Papadopoulos, et al.
Published: (2022-01-01)

Targeted nanopore sequencing for the identification of novel PRMT1 circRNAs unveils a diverse transcriptional profile of this gene in breast cancer cells
by: Maria Papatsirou, et al.
Published: (2024-03-01)

Monoclonal Gammopathy of Thrombotic Significance
by: Vasiliki Gkalea, et al.
Published: (2023-01-01)

Future Developments in the Treatment of AL Amyloidosis
by: Foteini Theodorakakou, et al.
Published: (2022-02-01)

PB2124: EFFICACY AND IMMUNE MODULATION OF DARATUMUMAB PLUS IMID COMBINATION IN PATIENTS REFRACTORY TO BOTH AGENTS“
by: Ioannis Kostopoulos, et al.
Published: (2023-08-01)

A novel microrna signature with clinical significance in multiple myeloma
by: A. Papanota, et al.
Published: (2020-10-01)

Deep Phenotyping Reveals Distinct Immune Signatures Correlating with Prognostication, Treatment Responses, and MRD Status in Multiple Myeloma
by: Konstantinos Papadimitriou, et al.
Published: (2020-11-01)

Multiple Myeloma and Thrombosis: Prophylaxis and Risk Prediction Tools
by: Despina Fotiou, et al.
Published: (2020-01-01)